Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition
Aileron And Advancium Sign Deal for ALRN-6924 Retinoblastoma Therapy
Details : Through the acquisition, Advancium will expand its oncology portfolio by acquiring ALRN-6924 (sulanemadlin), which is being evaluated for the treatment of retinoblastoma.
Product Name : ALRN-6924
Product Type : Large molecule
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Sulanemadlin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Advancium Health
Deal Size : Undisclosed
Deal Type : Acquisition